Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATYRNASDAQ:IDYANASDAQ:INDVNASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRAtyr PHARMA$5.39-2.0%$3.65$1.42▼$5.98$479.73M0.881.04 million shs2.08 million shsIDYAIDEAYA Biosciences$21.92-3.1%$18.65$13.45▼$44.42$1.92B0.041.02 million shs954,264 shsINDVIndivior$13.66-0.2%$11.03$7.33▼$17.09$1.88B0.661.09 million shs699,942 shsSDGRSchrödinger$26.69+2.1%$23.48$16.60▼$28.47$1.96B1.63885,141 shs1.46 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRAtyr PHARMA-2.00%+4.86%+66.36%+35.09%+538,999,900.00%IDYAIDEAYA Biosciences-3.14%+3.89%+19.46%+15.61%-41.67%INDVIndivior-0.22%-0.07%+20.46%+42.44%-19.03%SDGRSchrödinger+2.14%+12.47%+10.43%+21.71%+27.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATYRAtyr PHARMA2.7496 of 5 stars3.61.00.00.03.13.30.6IDYAIDEAYA Biosciences3.7969 of 5 stars3.52.00.04.42.31.70.0INDVIndivior2.5682 of 5 stars1.65.00.00.03.51.71.9SDGRSchrödinger1.5788 of 5 stars2.51.00.00.03.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATYRAtyr PHARMA 3.14Buy$18.60245.08% UpsideIDYAIDEAYA Biosciences 2.93Moderate Buy$54.27147.59% UpsideINDVIndivior 3.25Buy$15.009.81% UpsideSDGRSchrödinger 3.00Buy$32.8022.89% UpsideCurrent Analyst Ratings BreakdownLatest ATYR, IDYA, SDGR, and INDV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025ATYRAtyr PHARMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.005/22/2025IDYAIDEAYA BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.005/19/2025ATYRAtyr PHARMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.004/16/2025SDGRSchrödingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.003/14/2025ATYRAtyr PHARMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00(Data available from 6/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATYRAtyr PHARMA$235K2,041.41N/AN/A$1.54 per share3.50IDYAIDEAYA Biosciences$7M274.26N/AN/A$12.10 per share1.81INDVIndivior$1.17B1.61$2.77 per share4.94N/A∞SDGRSchrödinger$230.49M8.50$0.71 per share37.42$7.60 per share3.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATYRAtyr PHARMA-$50.39M-$0.81N/AN/AN/AN/A-79.44%-59.16%8/12/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.59N/AN/AN/AN/A-26.74%-25.54%8/5/2025 (Estimated)INDVIndivior$2M-$0.31N/A7.99N/A-3.96%-241.73%15.09%7/24/2025 (Estimated)SDGRSchrödinger$40.72M-$2.63N/AN/AN/A-91.84%-35.77%-24.51%7/30/2025 (Estimated)Latest ATYR, IDYA, SDGR, and INDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025ATYRAtyr PHARMA-$0.19-$0.17+$0.02-$0.17N/AN/A5/7/2025Q1 2025SDGRSchrödinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million5/6/2025Q1 2025IDYAIDEAYA Biosciences-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 million3/13/2025Q4 2024ATYRAtyr PHARMA-$0.23-$0.18+$0.05-$0.18$0.02 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATYRAtyr PHARMAN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ASDGRSchrödingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATYRAtyr PHARMA0.025.415.41IDYAIDEAYA BiosciencesN/A14.9722.93INDVIndiviorN/A0.830.65SDGRSchrödingerN/A4.114.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATYRAtyr PHARMA61.72%IDYAIDEAYA Biosciences98.29%INDVIndivior60.33%SDGRSchrödinger79.05%Insider OwnershipCompanyInsider OwnershipATYRAtyr PHARMA3.70%IDYAIDEAYA Biosciences2.50%INDVIndiviorN/ASDGRSchrödinger8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATYRAtyr PHARMA5389.00 million80.84 millionOptionableIDYAIDEAYA Biosciences8087.58 million84.47 millionOptionableINDVIndivior1,164137.88 millionN/ANot OptionableSDGRSchrödinger79073.38 million66.59 millionOptionableATYR, IDYA, SDGR, and INDV HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 11 at 9:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 10 at 9:00 AM | globenewswire.comSchrödinger, Inc. (NASDAQ:SDGR) Receives Average Recommendation of "Buy" from AnalystsJune 10 at 1:42 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 9 at 12:45 PM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 7, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 6, 2025 | globenewswire.comBronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities InvestigationJune 6, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to ConnectJune 5, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 5, 2025 | accessnewswire.com24,500 Shares in Schrödinger, Inc. (NASDAQ:SDGR) Acquired by Two Sigma Advisers LPJune 5, 2025 | marketbeat.comBank of America Corp DE Reduces Stock Position in Schrödinger, Inc. (NASDAQ:SDGR)June 5, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 4, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Shareholders to Reach OutJune 4, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Shareholders to Learn More About the InvestigationJune 3, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 3, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 2, 2025 | globenewswire.comBronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities InvestigationJune 2, 2025 | accessnewswire.comTwo Sigma Investments LP Acquires New Stake in Schrödinger, Inc. (NASDAQ:SDGR)June 2, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Investors to Learn More About the InvestigationJune 1, 2025 | accessnewswire.comSchrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and MarketingMay 30, 2025 | morningstar.comFraud Investigation Opened: Levi & Korsinsky Investigates Schrdinger, Inc. (SDGR) on Behalf of ShareholdersMay 30, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATYR, IDYA, SDGR, and INDV Company DescriptionsAtyr PHARMA NASDAQ:ATYR$5.39 -0.11 (-2.00%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$5.44 +0.04 (+0.83%) As of 06/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.IDEAYA Biosciences NASDAQ:IDYA$21.92 -0.71 (-3.14%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$21.90 -0.02 (-0.07%) As of 06/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Indivior NASDAQ:INDV$13.66 -0.03 (-0.22%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$13.66 0.00 (0.00%) As of 06/11/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Schrödinger NASDAQ:SDGR$26.69 +0.56 (+2.14%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$26.66 -0.04 (-0.13%) As of 06/11/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY GitLab: Buy It Low While You Still Can—Higher Prices Are Coming RKLB Breakout Fails Near Highs: Should Investors Be Concerned? Amazon Is on Track to Hit a Critical Level: Watch Out Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal Nintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive? Will Warner Bros. Discovery’s Split Produce Double the Upside? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
